Haemonetics Corporation (NYSE:HAE) Stock Has Average Target Price of $99.78

Haemonetics Corporation (NYSE:HAE – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the eleven ratings firms that are covering the firm, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold recommendation, six have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $99.78.

A number of research firms have commented on HAE. Raymond James Financial lifted their target price on Haemonetics from $105.00 to $125.00 and gave the stock an “outperform” rating in a report on Thursday, September 3rd. Weiss Ratings upgraded shares of Haemonetics from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, August 11th. Robert W. Baird lifted their price objective on shares of Haemonetics from $96.00 to $119.00 and gave the stock an “outperform” rating in a research note on Friday, August 21st. Barrington Research upped their price target on shares of Haemonetics from $95.00 to $118.00 and gave the company an “outperform” rating in a report on Wednesday, August 19th. Finally, BTIG Research lifted their price target on shares of Haemonetics from $96.00 to $110.00 and gave the company a “buy” rating in a research note on Tuesday, August 18th.

Get Haemonetics alerts:

Check Out Our Latest Report on Haemonetics

Hedge Funds Weigh In On Haemonetics

A number of large investors have recently made changes to their positions in HAE. EverSource Wealth Advisors LLC increased its holdings in shares of Haemonetics by 12.3% during the first quarter. EverSource Wealth Advisors LLC now owns 1,920 shares of the medical instruments supplier’s stock valued at $108,000 after acquiring an additional 211 shares in the last quarter. Expect Equity LLC boosted its stake in Haemonetics by 1.5% in the 4th quarter. Expect Equity LLC now owns 31,381 shares of the medical instruments supplier’s stock worth $2,515,000 after purchasing an additional 457 shares in the last quarter. GAMMA Investing LLC grew its position in Haemonetics by 133.4% during the 2nd quarter. GAMMA Investing LLC now owns 803 shares of the medical instruments supplier’s stock worth $60,000 after purchasing an additional 459 shares during the last quarter. HighTower Advisors LLC grew its position in Haemonetics by 2.7% during the 4th quarter. HighTower Advisors LLC now owns 17,642 shares of the medical instruments supplier’s stock worth $1,414,000 after purchasing an additional 472 shares during the last quarter. Finally, Kelleher Financial Advisors acquired a new position in Haemonetics during the 2nd quarter valued at approximately $38,000. 99.67% of the stock is owned by institutional investors and hedge funds.

Haemonetics Stock Up 0.1%

Shares of NYSE HAE opened at $104.77 on Friday. The firm has a market capitalization of $4.77 billion, a PE ratio of 51.36, a price-to-earnings-growth ratio of 2.10 and a beta of 0.61. The company has a current ratio of 3.08, a quick ratio of 1.91 and a debt-to-equity ratio of 1.40. The firm has a fifty day simple moving average of $99.40 and a two-hundred day simple moving average of $77.74. Haemonetics has a 12 month low of $48.17 and a 12 month high of $110.45.

Haemonetics (NYSE:HAE – Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $1.14 earnings per share for the quarter, topping the consensus estimate of $1.08 by $0.06. Haemonetics had a return on equity of 27.55% and a net margin of 7.12%.The company had revenue of $339.38 million for the quarter, compared to analysts’ expectations of $327.86 million. During the same period in the prior year, the firm earned $1.10 earnings per share. The firm’s revenue for the quarter was up 5.5% on a year-over-year basis. Equities analysts expect that Haemonetics will post 5.29 earnings per share for the current year.

About Haemonetics

(Get Free Report)

Haemonetics Corporation (NYSE: HAE) is a medical technology company that develops and supplies products and software for blood management. Its solutions are used to collect, process, manage and analyze blood and blood components, helping healthcare providers and blood and plasma collection organizations improve the availability, safety and efficiency of transfusion-related care.

The company’s portfolio includes plasma and blood component collection systems, disposable collection and processing kits, surgical blood recovery and autotransfusion systems, and technologies used to assess coagulation and hemostasis.

Featured Stories

• Five stocks we like better than Haemonetics
• Could Nike’s Brutal Sell-Off Finally Be Running Out of Steam?
• The AI Buildout Needs Power It Cannot Get: 4 Energy Stocks Already Have It
• McDonald’s Is Undergoing a Massive New Growth Strategy. Can It Win Back Consumers?
• MGM Resorts Stock Sinks After Diller Deal Collapse: Overreaction or Warning?

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.